On Tuesday, AbCellera Biologics Inc (NASDAQ: ABCL) was -1.79% drop from the session before settling in for the closing price of $3.36. A 52-week range for ABCL has been $2.34 – $5.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 476.52%. When this article was written, the company’s average yearly earnings per share was at -15.13%. With a float of $221.93 million, this company’s outstanding shares have now reached $295.16 million.
Let’s determine the extent of company efficiency that accounts for 586 employees. In terms of profitability, gross margin is -179.73%, operating margin of -934.58%, and the pretax margin is -613.32%.
AbCellera Biologics Inc (ABCL) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward AbCellera Biologics Inc stocks. The insider ownership of AbCellera Biologics Inc is 24.86%, while institutional ownership is 34.54%.
AbCellera Biologics Inc (ABCL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -15.13% per share during the next fiscal year.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
You can see what AbCellera Biologics Inc (ABCL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Looking closely at AbCellera Biologics Inc (NASDAQ: ABCL), its last 5-days average volume was 5.3 million, which is a jump from its year-to-date volume of 4.11 million. As of the previous 9 days, the stock’s Stochastic %D was 66.70%. Additionally, its Average True Range was 0.22.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 71.75%, which indicates a significant increase from 58.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.34% in the past 14 days, which was higher than the 63.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.96, while its 200-day Moving Average is $3.06. However, in the short run, AbCellera Biologics Inc’s stock first resistance to watch stands at $3.40. Second resistance stands at $3.49. The third major resistance level sits at $3.61. If the price goes on to break the first support level at $3.18, it is likely to go to the next support level at $3.07. Should the price break the second support level, the third support level stands at $2.97.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
There are 295,366K outstanding shares of the company, which has a market capitalization of 974.71 million. As of now, sales total 38,030 K while income totals -146,400 K. Its latest quarter income was 6,510 K while its last quarter net income were -51,110 K.
